Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ingela Claesson"'
Autor:
Karin Sundfeldt, Karolina Partheen, Kristina Levan, Ghita Fallenius, György Horvath, Ingela Claesson, Lovisa Österberg
Publikováno v:
International Journal of Cancer. 123:2130-2137
The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd366cc68c537d2c70b84ad25a1b369
https://doi.org/10.1002/ijc.23758
https://doi.org/10.1002/ijc.23758
Autor:
Stig Palm, Tom Bäck, Lars Jacobsson, Ingela Claesson, Sture Lindegren, Håkan Andersson, Elisabet Warnhammar, Marita Olsson, Jörgen Elgqvist, Ragnar Hultborn, Holger Jensen
Publikováno v:
Nuclear Medicine and Biology. 33:1065-1072
OBJECTIVE: The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice. The study was performed using the monoclonal antibody MX35 F(ab')(2) labeled with the alp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f8b9bb65b9c4d8fbe9e6793606dab6
https://doi.org/10.1016/j.nucmedbio.2006.07.009
https://doi.org/10.1016/j.nucmedbio.2006.07.009
Autor:
Sofia H.L. Frost, Stig Palm, Tom Bäck, Anna Danielsson, Jörgen Elgqvist, Ingela Claesson, Holger Jensen, Sture Lindegren, Lars Jacobsson, Ragnar Hultborn
Publikováno v:
International journal of radiation oncology, biology, physics. 69(2)
PURPOSE: To investigate the potential use of astatine-211 (211At)-labeled trastuzumab for the treatment of HER-2-positive, radioresistant ovarian carcinoma. METHODS AND MATERIALS: Four-week-old nude mice were inoculated intraperitoneally with 5 . 10(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34719be6b17b2fe8080a8b3a3f161062
https://pubmed.ncbi.nlm.nih.gov/17869670
https://pubmed.ncbi.nlm.nih.gov/17869670
Autor:
Jörgen, Elgqvist, Håkan, Andersson, Tom, Bäck, Ingela, Claesson, Ragnar, Hultborn, Holger, Jensen, Bengt R, Johansson, Sture, Lindegren, Marita, Olsson, Stig, Palm, Elisabet, Warnhammar, Lars, Jacobsson
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 47(8)
The purpose of this work was to (a) investigate the efficacy of radioimmunotherapy using 211At-MX35 F(ab')2 or 211At-Rituximab F(ab')2 (nonspecific antibody) against differently advanced ovarian cancer in mice; (b) image the tumor growth on the perit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c882568b9a8c791394bc9f6a84440bd
https://pubmed.ncbi.nlm.nih.gov/16882999
https://pubmed.ncbi.nlm.nih.gov/16882999
Autor:
Håkan Andersson, Marita Olsson, Stig Palm, Ingela Claesson, Tom Bäck, Lars Jacobsson, Ragnar Hultborn, Jörgen Elgqvist, Holger Jensen, Elisabet Warnhammar, Sture Lindegren, Peter Bernhardt, Bengt Johansson
Publikováno v:
International journal of radiation oncology, biology, physics. 66(4)
PURPOSE: To elucidate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice. This study: (i) estimated the minimum required activity (MRA), giving a reasonable high therapeutic efficacy; and (ii) calculated the specific energ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bdb92646b3def4a10cf2e70e9b8add3
https://pubmed.ncbi.nlm.nih.gov/17145538
https://pubmed.ncbi.nlm.nih.gov/17145538
Autor:
Stig, Palm, Tom, Bäck, Ingela, Claesson, Ulla, Delle, Ragnar, Hultborn, Sture, Lindegren, Lars, Jacobsson
Publikováno v:
Anticancer research. 23(2B)
New data on the biological effect of 211At-C215 monoclonal antibody in a slowly rotating, widely dispersed single-cell suspension of the human cancer cell line Colo-205 is presented. Cell growth curves of each experiment were used to calculate an app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b5f4c7842cab3929ec858ff60029a6b
https://pubmed.ncbi.nlm.nih.gov/12820374
https://pubmed.ncbi.nlm.nih.gov/12820374
Autor:
Karin Sundfeldt, Ingela Claesson, Kristina Levan, György Horvath, Lovisa Österberg, Karolina Partheen
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 336 (2009)
BMC Cancer
BMC Cancer
Background The majority of women with ovarian cancer are diagnosed in late stages, and the mortality rate is high. The use of biomarkers as prognostic factors may improve the treatment and clinical outcome of these patients. We performed an external
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::973cba9e512248014e4d18d6be5a6eec